Novartis investors were disappointed when CEO Joe Jimenez said that a decision about eye unit Alcon would be delayed.
Still struggling to turn its manufacturing around, Dr. Reddy's is recalling 569,000 store-brand famotidine tablets in the U.S.
Merck & Co. plans to jettison three U.S. sales teams and 1,800 associated staffers while creating a new, 960-employee chronic care force.
With an FDA committee nod, Novo Nordisk is one step closer to rolling out its key diabetes drug semaglutide—and launch preps are underway.
What comes after a successful M&A hunt at Gilead Sciences? A promotion for the executive who sewed up its $11.9 billion deal for Kite Pharma.
FDA reviewers flagged data on cardiovascular benefits—and potential eye risks—posed by Novo Nordisk's semaglutide, up for approval later this year.
Novartis has decided not to sell its $14 billion Roche stake, but that doesn't mean its strategic revamp is over.
BDO sifted through SEC filings to discover just what the top 100 life sciences companies are most worried about these days.
Flexion's Zilretta won approval on Friday, with its official label winning praise from executives and analysts.
For Novo Nordisk and its new fast-acting mealtime insulin, a second try at the FDA gatekeepers was enough to secure an approval.